Timing matters: study looks at when to start MS drug kesimpta
NCT ID NCT05776888
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This study watches 106 people with relapsing multiple sclerosis in Austria to see if starting the drug Ofatumumab (Kesimpta) earlier makes a difference compared to starting it later. Over 2 years, researchers track how well the drug controls relapses, brain lesions, and disability progression. The goal is to learn the best timing for treatment in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.